Literature DB >> 20107769

Species differences in expression pattern of arginase isoenzymes and differential effects of arginase inhibition on collagen synthesis in human and rat pulmonary fibroblasts.

M Warnken1, S Haag, S Matthiesen, U R Juergens, K Racké.   

Abstract

Arginase was shown to be up-regulated in different animal models of inflammatory and fibrotic airway diseases. Since arginase provides L-ornithine, one precursor for L-proline, an essential substrate for collagen synthesis, it has been suggested that arginase might be a key enzyme in airway remodelling. The present study aimed to characterize expression of arginase isoenzymes in rat and human pulmonary fibroblasts, and to test whether arginase inhibition affects collagen synthesis. In primary rat tracheal and lung fibroblasts, mRNA for arginase I and II could be detected, with arginase I as predominant isoenzyme. In contrast, in human lung fibroblasts (primary cells and different cells lines) mRNA levels for arginase I were at or below detection limit whereas arginase II mRNA was markedly higher than in rat pulmonary fibroblasts. Arginase activity in rat tracheal and lung fibroblasts was between 20 and 30 mU/mg protein, but was below detection limit (2.5 mU/mg) in human lung fibroblasts. In rat tracheal and lung fibroblasts cultured in proline-free medium, arginase inhibition by N(omega)-hydroxy-nor-L-arginine caused a reduction by about one-third of basal collagen I accumulation (determined by western blot analysis) and largely attenuated transforming growth factor beta 1 (TGF-beta(1))-induced increase in collagen accumulation, whereas basal and TGF-beta(1)-induced collagen accumulation by human lung fibroblasts was not affected by arginase inhibition. In conclusion, arginase isoenzymes reveal a species specific expression pattern. Arginase contributes significantly to L-proline supply for collagen synthesis in rat fibroblasts, in which arginase I is the predominant isoenzyme, but not in human fibroblasts, in which arginase II is the only isoenzyme expressed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107769     DOI: 10.1007/s00210-009-0489-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  Inhibition of arginase in rat and rabbit alveolar macrophages by N omega-hydroxy-D,L-indospicine, effects on L-arginine utilization by nitric oxide synthase.

Authors:  C Hey; J L Boucher; S Vadon-Le Goff; G Ketterer; I Wessler; K Racké
Journal:  Br J Pharmacol       Date:  1997-06       Impact factor: 8.739

2.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells.

Authors:  M Munder; K Eichmann; J M Morán; F Centeno; G Soler; M Modolell
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

3.  Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum.

Authors:  N N Kim; J D Cox; R F Baggio; F A Emig; S K Mistry; S L Harper; D W Speicher; S M Morris; D E Ash; A Traish; D W Christianson
Journal:  Biochemistry       Date:  2001-03-06       Impact factor: 3.162

4.  Modulation of cholinergic airway reactivity and nitric oxide production by endogenous arginase activity.

Authors:  H Meurs; M A Hamer; S Pethe; S Vadon-Le Goff; J L Boucher; J Zaagsma
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness.

Authors:  Herman Meurs; Sue McKay; Harm Maarsingh; Marco A M Hamer; Lejla Macic; Niek Molendijk; Johan Zaagsma
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 6.  Human monocytes/macrophages: NO or no NO?

Authors:  M Denis
Journal:  J Leukoc Biol       Date:  1994-05       Impact factor: 4.962

Review 7.  Arginine metabolism: nitric oxide and beyond.

Authors:  G Wu; S M Morris
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

Review 8.  Arginine metabolism: boundaries of our knowledge.

Authors:  Sidney M Morris
Journal:  J Nutr       Date:  2007-06       Impact factor: 4.798

9.  Effects of phosphodiesterase inhibitors on L-arginine pathways in rat alveolar macrophages.

Authors:  Sahra Koschorreck; Folker Wenzel; Margarita Fuhrmann; Kurt Racké
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

10.  Role of Epac1 in mediating anti-proliferative effects of prostanoid EP(2) receptors and cAMP in human lung fibroblasts.

Authors:  S Haag; M Warnken; U R Juergens; K Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-22       Impact factor: 3.000

View more
  3 in total

1.  Arginase impedes the resolution of colitis by altering the microbiome and metabolome.

Authors:  Julia Baier; Maximilian Gänsbauer; Claudia Giessler; Harald Arnold; Mercedes Muske; Ulrike Schleicher; Sören Lukassen; Arif Ekici; Manfred Rauh; Christoph Daniel; Arndt Ha Rtmann; Benjamin Schmid; Philipp Tripal; Katja Dettmer; Peter J Oefner; Raja Atreya; Stefan Wirtz; Christian Bogdan; Jochen Mattner
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

2.  Modulation of Arginase-2 mRNA Levels by ω-3 PUFAs and Aspirin in Asthmatic Human Lung Fibroblasts.

Authors:  Vamsee K Duggirala; Kyla Geary; Donald Hasenmayer; Farzaneh Daghigh
Journal:  J Lipids       Date:  2022-08-25

3.  Comparative study of the effects of fetal bovine serum versus horse serum on growth and differentiation of primary equine bronchial fibroblasts.

Authors:  Jana Franke; Vanessa Abs; Claudia Zizzadoro; Getu Abraham
Journal:  BMC Vet Res       Date:  2014-05-26       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.